This post was originally published on this site

Stocks were mixed Tuesday following a Wall Street rally that was fueled by optimism over a possible coronavirus vaccine.

© TheStreet Dow Rises, Nasdaq Drops After Tech Sector Lags

The Dow Jones Industrial Average rose 238 points, or 0.82%, to 29,396, the S&P 500 declined 0.09% and the Nasdaq dropped 1.2%.

Technology shares – big winners during the coronavirus pandemic – were the leading laggards again Tuesday following Pfizer’s announcement Monday that its coronavirus drug candidate being developed with partner BioNTech prevented more than 90% of infections in a large-scale study.

On Monday, the tech-heavy Nasdaq tumbled 1.53% as stay-at-home stocks such as that have thrived during the pandemic fell on the Pfizer vaccine news.

Video: Health-care stocks surge with election outcome still uncertain — What it could mean for the sector’s future (CNBC)

Health-care stocks surge with election outcome still uncertain — What it could mean for the sector’s future
What to watch next

Amazon again traded lower Tuesday after the European Union filed formal charges against the online retail giant for alleged unfair business practices.

Load Error

Boeing rose sharply amid reports that its grounded 737 MAX aircraft could be cleared for return by as early as next week.

“Investors need to diversify toward more cyclical parts of the market that have lagged behind in 2020, and away from big tech and the primary stay-at-home beneficiaries,” said Mark Haefele, chief investment officer at UBS Global Wealth Management.

Despite the Pfizer news, experts cautioned Tuesday that mass deployment of a vaccine remains months away. President-elect Joe Biden also issued a warning the same day he unveiled a new coronavirus task force and the U.S. recorded its 10 millionth coronavirus case and hospitalizations rose to a record high of just more than 59,000.

“There’s a need for bold action to fight this pandemic. We’re still facing a very dark winter,” Biden said.

Eli Lilly was rising Tuesday after it received emergency clearance from the Food and Drug Administration for an antibody treatment used in patients suffering mild to moderate cases of Covid-19, the disease caused by the coronavirus.

This article was originally published by TheStreet.

Continue Reading